AI-generated summary
This randomized placebo-controlled trial compared photobiomodulation with placebo in 44 hemodialysis patients with chronic kidney disease. The authors report that photobiomodulation was associated with increased salivary flow and lower saliva urea levels, with no change in total protein or calcium. The authors suggest the findings are promising but the abstract does not describe long-term outcomes.
- Participants
- 44
- Who or what was studied
- Patients with chronic kidney disease on hemodialysis
- Wavelengths
- 808 nm
- Limits stated in the abstract
- The abstract reports only a short follow-up of 14 days and does not describe the sample size calculation or long-term outcomes.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 808 nm
- Energy density (fluence)
- 142 J/cm2
- Power
- 100 mW
- Total energy
- 4 J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Placebo-controlled. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.